Drug intelligence / Profile preview

PCV001

Development stage: Unknown
Lead developer: IngeneOx Therapeutics
Modality: Vaccines & Immunotherapeutics

Overview

PCV001 is a cancer vaccine being developed by Celleron Therapeutics (now IngenOx Therapeutics) for the treatment of colorectal cancer. The vaccine is designed to target specific cancer-associated antigens to stimulate a host immune response against tumor cells. By presenting these antigens to the immune system, PCV001 aims to induce a targeted T-cell response to recognize and eliminate colorectal cancer cells. It is currently in Phase 1 clinical development as part of the company's oncology pipeline.

Beyond the preview

Go deeper on PCV001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCV001.

Explore the full profile